Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.

Therapeutics

Pharmaceutical

Biotechnology

Heptares Therapeutics

Chris Cargill

Mariko Nakafuji

Takuya Saiki

Shinichiro N.

Nigel Swain

Matthew Foxwell

Matt Barnes

Mathieu Rappas

Kieran Johnson

Jayesh Patel

Hironoshin Nomura

Helen Carberry

Gerry McAnally

Gareth Waldron

Chris de Graaf

Candelle Chong

The Leadership Team at Heptares Therapeutics drives the strategic direction and operational effectiveness of the company, focusing on advancing drug discovery initiatives targeting GPCRs. Comprising a diverse group of executives, including the CEO, CFO, and heads of various departments, the team collaborates to optimize corporate strategy, oversee financial performance, and ensure compliance while fostering innovation in drug development and research.

Leadership Team

Research and Development Scientists

Finance & Accounting

Leadership Team

About

Team members

Other teams at Heptares Therapeutics

Research and Development Scientists

Finance & Accounting